Human Retroviral Infections [electronic resource] : Immunological and Therapeutic Control /

The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established “cure” for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability.

Saved in:
Bibliographic Details
Main Authors: Ugen, Kenneth E. editor., Bendinelli, Mauro. editor., Friedman, Herman. editor., SpringerLink (Online service)
Format: Texto biblioteca
Language:eng
Published: Boston, MA : Springer US, 2002
Subjects:Medicine., Immunology., Laboratory medicine., Medical microbiology., Human anatomy., Infectious diseases., Pathology., Medicine & Public Health., Infectious Diseases., Medical Microbiology., Laboratory Medicine., Anatomy.,
Online Access:http://dx.doi.org/10.1007/b111099
Tags: Add Tag
No Tags, Be the first to tag this record!
id KOHA-OAI-TEST:201271
record_format koha
institution COLPOS
collection Koha
country México
countrycode MX
component Bibliográfico
access En linea
En linea
databasecode cat-colpos
tag biblioteca
region America del Norte
libraryname Departamento de documentación y biblioteca de COLPOS
language eng
topic Medicine.
Immunology.
Laboratory medicine.
Medical microbiology.
Human anatomy.
Infectious diseases.
Pathology.
Medicine & Public Health.
Infectious Diseases.
Medical Microbiology.
Immunology.
Pathology.
Laboratory Medicine.
Anatomy.
Medicine.
Immunology.
Laboratory medicine.
Medical microbiology.
Human anatomy.
Infectious diseases.
Pathology.
Medicine & Public Health.
Infectious Diseases.
Medical Microbiology.
Immunology.
Pathology.
Laboratory Medicine.
Anatomy.
spellingShingle Medicine.
Immunology.
Laboratory medicine.
Medical microbiology.
Human anatomy.
Infectious diseases.
Pathology.
Medicine & Public Health.
Infectious Diseases.
Medical Microbiology.
Immunology.
Pathology.
Laboratory Medicine.
Anatomy.
Medicine.
Immunology.
Laboratory medicine.
Medical microbiology.
Human anatomy.
Infectious diseases.
Pathology.
Medicine & Public Health.
Infectious Diseases.
Medical Microbiology.
Immunology.
Pathology.
Laboratory Medicine.
Anatomy.
Ugen, Kenneth E. editor.
Bendinelli, Mauro. editor.
Friedman, Herman. editor.
SpringerLink (Online service)
Human Retroviral Infections [electronic resource] : Immunological and Therapeutic Control /
description The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established “cure” for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability.
format Texto
topic_facet Medicine.
Immunology.
Laboratory medicine.
Medical microbiology.
Human anatomy.
Infectious diseases.
Pathology.
Medicine & Public Health.
Infectious Diseases.
Medical Microbiology.
Immunology.
Pathology.
Laboratory Medicine.
Anatomy.
author Ugen, Kenneth E. editor.
Bendinelli, Mauro. editor.
Friedman, Herman. editor.
SpringerLink (Online service)
author_facet Ugen, Kenneth E. editor.
Bendinelli, Mauro. editor.
Friedman, Herman. editor.
SpringerLink (Online service)
author_sort Ugen, Kenneth E. editor.
title Human Retroviral Infections [electronic resource] : Immunological and Therapeutic Control /
title_short Human Retroviral Infections [electronic resource] : Immunological and Therapeutic Control /
title_full Human Retroviral Infections [electronic resource] : Immunological and Therapeutic Control /
title_fullStr Human Retroviral Infections [electronic resource] : Immunological and Therapeutic Control /
title_full_unstemmed Human Retroviral Infections [electronic resource] : Immunological and Therapeutic Control /
title_sort human retroviral infections [electronic resource] : immunological and therapeutic control /
publisher Boston, MA : Springer US,
publishDate 2002
url http://dx.doi.org/10.1007/b111099
work_keys_str_mv AT ugenkennetheeditor humanretroviralinfectionselectronicresourceimmunologicalandtherapeuticcontrol
AT bendinellimauroeditor humanretroviralinfectionselectronicresourceimmunologicalandtherapeuticcontrol
AT friedmanhermaneditor humanretroviralinfectionselectronicresourceimmunologicalandtherapeuticcontrol
AT springerlinkonlineservice humanretroviralinfectionselectronicresourceimmunologicalandtherapeuticcontrol
_version_ 1756267541299200000
spelling KOHA-OAI-TEST:2012712018-07-30T23:28:10ZHuman Retroviral Infections [electronic resource] : Immunological and Therapeutic Control / Ugen, Kenneth E. editor. Bendinelli, Mauro. editor. Friedman, Herman. editor. SpringerLink (Online service) textBoston, MA : Springer US,2002.engThe discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established “cure” for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability.The Two Principal Viremias of HIV -- Potential Role of Human T-cell Leukemia/Lymphoma Viruses (HTLV) in Diseases Other Than Acute T-cell Leukemia/Lymphoma (ATL) -- Viral-Related Proteins in Immune Dysfunction Associated with AIDS -- Carbohydrate Interactions and HIV-1 -- HTLV-I and HTLV-II Infection -- Vaccine Approaches for Human T-cell Lymphotropic Virus Type I -- Immune Responses againstHIV-2 -- HIV Mucosal Vaccines -- Nucleic Acid Vaccination against HIV-1 -- Passive Immunotherapy against HIV-1 -- Human Immunodeficiency Virus Type 1 Accessory Genes -- A New Generation of Antiviral Therapeutics Designed to Prevent the Use of Chemokine Receptors for Entry by HIV-1 -- Protease Inhibitors and HIV-1 Genetic Variability in Infected Children -- Gene Therapy and HIV-1 Infection -- Pediatric HIV.The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established “cure” for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability.Medicine.Immunology.Laboratory medicine.Medical microbiology.Human anatomy.Infectious diseases.Pathology.Medicine & Public Health.Infectious Diseases.Medical Microbiology.Immunology.Pathology.Laboratory Medicine.Anatomy.Springer eBookshttp://dx.doi.org/10.1007/b111099URN:ISBN:9780306468193